Seneca Therapeutics To Host a Key Opinion Leader Webinar on Seneca Valley Virus and TEM 8 On Wednesday, March 16th @ 2pmET - read this article along with other careers information, tips and advice on BioSpace
Reflection celebrates success and ponders lessons learned in research and educational activities.
Crystal Levesque, Christian Ramirez-Camba, Ryan Samuel, Jeff Clapper, Xufei Yang, and Robert Thaler, South Dakota State University | Jan 21, 2021
Like many others, January at South Dakota State University represents an opportunity to reflect on successes (and failures) in research and educational activities. Approximately 4.5 years ago we embarked on a new era of swine research when the first gilts arrived at our new sow unit. Support from the U.S. swine industry and partnering groups for the farrow-to-finish unit and the 1,200 head commercial wean-to-finish barn was beyond expectations.The goal of these units is to train the next generation of pork producers and leaders through education and research activities using the latest technologies. As we reflect over what went right, what we can improve on, and what the future might hold, here is a summary of the research outputs from
Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass.
pipeline of intratumorally and intravenously administered viral immunotherapies – Initial phase of site buildout anticipated to be completed in fourth quarter 2021 Company anticipates site will be fully operational in early 2023 and expects to
employ up to 100 Oncorus team members
CAMBRIDGE, Mass., Jan. 04, 2021 Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, announced today that it has signed a 15-year lease to build a state-of-the-art, 88,000 square foot Good Manufacturing Practice (GMP) viral immunotherapy clinical manufacturing facility in Andover, Mass.
Oncorus is advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple cancer indications with significant unmet needs based on its oncolytic Herpes S